

June 21, 2019
Rena Therapeutics Inc.

Notice of laboratory relocation

Rena Therapeutics Inc. (President & CEO: Jun Sasaki, headquarters: Chiyoda-ku, Tokyo, hereinafter referred to as “Rena”) moved the R&D operation to the following address. Rana aims to improve the efficiency and quality of its R & D at the new facility to accelerate the commercialization of HDO technology.

1. Transfer destination: 2-26-1, Muraoka Higashi, Fujisawa City, Kanagawa
2. Relocation date: June 21, 2019

[About Rena]

Rena is a Japanese corporation established in 2015, a bio-venture company authorized by TMDU, having its office at Otemachi Financial City Grand Cube 3F, 9-2, Otemachi 1-chome, Chiyoda-ku, Tokyo 100-0004, Japan.

Nucleic acid drugs have been recognized issues such as delivery to a disease site, side effects and stability in blood after administration, but on the other hand, they have advantage to be able to approach to diseases in which they were difficult to apply therapy using low-molecular-weight compounds, antibodies, etc.

HDO has a structure combining an antisense strand (= active chain) (double stranded upper part) functioning as an active body and a carrier chain (lower part) containing a ligand for carrying an antisense strand to a disease site. By adopting such a structure, it is expected that the antisense effect can be implemented more effectively in the target organ than the conventional single-stranded antisense nucleic acid.





Rena has a business model that provides solutions and services based on HDO technology as a platform to customers and receives consideration.

After establishing in January 2015, Rena has raised funds twice. As a result, we will strengthen the HDO technology, we have already signed collaborative research agreements with two major pharmaceutical companies already, and will continue to increase the number of contracts with pharmaceutical companies and will further strengthen our business foundation.

Rena is committed and responsible for creating novel nucleic acid drugs using HDO in order to respond to unmet medical needs such as cancer, neurodegenerative diseases, hereditary diseases and other difficult diseases.

(For inquiries about this announcement)

Contact Manager: Shoichi Iwamoto, General Manager

Rena Therapeutics Inc.

Phone number +81-3-4243-6081

E-mail: info@renatherapeutics.com

End of announcement